In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Video series: The 3 Cs" of the data journey"
This three part video series examines some of the factors that should be considered to ensure that clinical trial data captured via wearable devices, is monitored expeditiously and effectively.
-
Bringing the fight to antimicrobial resistance: What COVID-19 has taught us about how to face a growing emergency
Dr. Johan Du Toit, Executive Director, Internal Medicine, considers strategies from COVID era clinical trials for addressing the public health crisis of antimicrobial resistance.
-
-
Operationalising decentralised clinical trials
In this article, our experts discuss the challenges and change management approaches that ICON faced during the COVID-19 pandemic, and how we overcame them through the use of decentralised and hybrid clinical trials (see page 14).
-
4D pharma enlists ICON for upcoming phase I/II microbiome therapeutic combo study in urothelial carcinoma with Merck KGaA’s Bavencio
This article announces that 4D Pharma are working with ICON for an upcoming trial with its lead live biotherapeutic MRx0518 in combination with Merck KGaA’s Bavencio. (a subcription is required to view this article)
-
On the frontlines of the COVID-19 crisis
In this report, Dr Steve Cutler describes ICON’s efforts to combat the COVID-19 pandemic and how the crisis has pushed new digital technologies forward
-
R&D outsourcing trends roundtable
Solomon Babani, SVP and General Partner, Biotech and Small/Mid-Size Pharma, contributes to this article on today’s R&D outsourcing trends across drug development, clinical trial services and manufacturing.
-
Irish businesses back global vaccine drive
This article summarises the companies, including ICON, who are backing UNICEF’s drive to supply 2 billion vaccines to the developing world.
-
-
The changing pace of vaccines: How COVID-19 has impacted the future of infectious disease vaccine development
Shelley McLendon considers the knock-on effect of COVID-19 for other infectious diseases, and what we can do to speed up development future vaccines
